2,3 REDEFINE 1 was a 68-week, double-blind, randomized, placebo- and active-controlled phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus cagrilintide 2.4 mg monotherapy, semaglutide 2.4 mg monotherapy, and placebo, all in combination with lifestyle intervention in 3,417 adults with obesity or overweight with one or more obesity-related complications and without type 2 diabetes
While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only
External Resources & References Sikiric et al
You don't need an appointment
As we know, the RAAS system has traditionally been viewed as the bodys primary mechanism for regulating blood pressure, [] READ ARTICLE Peptide World Congress 2026 At Peptide World Congress 2026, join the fastest-growing community of evidence-based providers exploring the therapeutic power of clinical peptides
An experimental model of prolonged esophagitis with sphincter failure in the rat and the therapeutic potential of gastric pentadecapeptide BPC 157
